Capivasertib is an aminopiperidine compound that functions as a pan-AKT kinase inhibitor. It is used as a pharmaceutical raw material in combination with fulvestrant for the manufacturing of therapies targeting hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer with specific PIK3CA/AKT1/PTEN alterations.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1143532-39-1
Ethyl (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoate
pharmaceutical raw material
Losartan
pharmaceutical raw material
Fondaparinux sodium
pharmaceutical raw material
Trabectedin
pharmaceutical raw material
(S)-tert-butyl 4-(1-(4-chlorophenyl)-3-hydroxypropylcarbamoyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-ylcarbamate
research compound
4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide
JDUBGYFRJFOXQC-KRWDZBQOSA-N
C1CN(CCC1(C(=O)N[C@@H](CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4